Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
115年第1季綜合損益表
Interim / Quarterly Report Classification · 92% confidence The document is a consolidated comprehensive income statement (“合併綜合損益表”) for the first quarter of the fiscal year (民國115年第1季), with detailed financial line items and amounts. It presents substantive financial data for a period shorter than a full fiscal year, indicating it is the actual interim/quarterly report rather than an announcement or summary. Therefore, it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-12 Chinese
115年第1季資產負債表
Interim / Quarterly Report Classification · 90% confidence The document presents detailed financial statements (a combined balance sheet) for the first quarter (“115年第1季”), including assets, liabilities, and equity with actual figures. It clearly contains substantive quarterly financial data rather than just an announcement or summary, so it qualifies as an Interim/Quarterly Report. Q1 2026
2026-05-12 Chinese
公告董事會決議通過增資新加坡子公司Lotus International Pte. Ltd.
Share Issue/Capital Change Classification · 92% confidence The document is a statutory disclosure on Taiwan’s MOPS platform announcing a board resolution to increase capital in the company’s 100%-owned Singapore subsidiary. It details the share issuance (unit price, total amount, number of shares) and related party transaction information. This is not an earnings release, interim report, or a regular publication announcement, but rather a capital change event. Therefore, it falls under the “Share Issue/Capital Change” category (SHA).
2026-05-11 Chinese
本公司處分日本子公司Lotus Japan Holdings Co., Ltd.之100%所有權
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure filed on the Taiwan public information observation platform detailing the company’s disposal of its 100%-owned Japanese subsidiary (Lotus Japan Holdings Co., Ltd.). It provides transactional details (date, board approval, consideration, related parties, accounting ratios, etc.) but does not constitute an investor presentation, financial report, share issuance, earnings release, or other specific category. It is a general regulatory announcement of a material asset transaction that does not neatly fit the other specialized categories, so it defaults to Regulatory Filings (RNS).
2026-05-11 Chinese
公告本公司董事會決議通過115年第一季財務報告
Interim / Quarterly Report Classification · 88% confidence The document is a formal announcement from a listed company (美時, ticker 1795) via the Taiwan “公開資訊觀測站” that its board approved the 115-year first quarter (“第一季”) financial report. It provides substantive financial data (revenue, profits, EPS, assets, liabilities, equity) for the period 115/01/01–115/03/31. This is a quarterly (interim) financial report, not merely an earnings press release or a notice of publication. Hence, it fits the Interim/Quarterly Report category (IR). Q1 2026
2026-05-11 Chinese
115年4月背書保證與資金貸與
Regulatory Filings Classification · 85% confidence The document is a routine disclosure of the company’s intercompany fund loans and guarantee and endorsement information for the month. It does not present a full financial report (e.g., interim or annual report), nor announce management changes, dividends, or other corporate actions. It is a regulatory compliance filing containing periodic credit/guarantee data. Therefore it falls into the general Regulatory Filings category (RNS).
2026-05-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.